CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) such as programmed cell death‐1 (PD‐1)/programmed cell death ligand‐1 (PD‐L1) antibodies have led to unprecedented durable clinical benefit for NSCLC, but response rates are low for patients with targetable driver mutations.15